Balchem Corporation reports developments tied to its specialty ingredient manufacturing business for health, nutrition, agriculture, healthcare, and other industrial markets. The company operates through Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, with recurring updates on segment sales, earnings, cash flow, debt, share repurchases, and conference participation.
Company news also includes product and market developments such as customized food and beverage ingredient systems, key nutrients for food, supplement, and pharmaceutical applications, animal nutrition products, choline chloride, specialty-packaged chemicals, and chelated minerals for micronutrient agriculture. Updates have included the Metalosate® T.E.A.M.™ plant tissue analysis platform and trade actions affecting choline chloride supply chains.
Balchem (NASDAQ: BCPC) reported third quarter fiscal 2025 results for the period ended September 30, 2025: net sales $267.6M (up 11.5% vs. prior year), net earnings $40.3M (up 19.1%), adjusted EBITDA $71.4M (up 11.0%), and free cash flow $50.7M. Cash from operations was $65.6M. Net debt was reduced to $88.9M with a leverage ratio of 0.3x. The Human Nutrition and Health segment reported record sales of $174.1M (up 14.3%).
Recent milestones include approvals to build a new microencapsulation facility in Orange County, NY, and five new sponsored research studies published in the quarter, including a choline biomarker study.
Balchem (NASDAQ: BCPC) will hold a conference call on Tuesday, October 21, 2025 at 11:00 AM ET to review third quarter 2025 results. The company said results and accompanying financial exhibits will be released prior to the market open on October 21, 2025.
Management presenters are Ted Harris, Chairman, President and CEO, and Martin Bengtsson, CFO. Institutional investors and analysts can join by dial-in numbers provided, and the public may listen via a live webcast at https://events.q4inc.com/attendee/857727932. A replay will be available at the same link for one year after the call.
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer focused on health and nutrition markets, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 9, 2025.
The company will be represented by key executives including Ted Harris (Chairman, President and CEO), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director of Investor Relations).
Balchem Corporation (NASDAQ: BCPC) reported strong Q2 2025 financial results with record net sales of $255.5 million, up 9.1% year-over-year. The company achieved net earnings of $38.3 million, a 19.4% increase, and record adjusted EBITDA of $69.2 million, up 11.2%.
All three business segments showed growth, with Human Nutrition and Health achieving record sales of $160.8 million (up 8.7%), Animal Nutrition and Health reaching $56.0 million (up 13.1%), and Specialty Products posting record sales of $37.2 million (up 6.0%).
Key developments include plans for a new $36 million micro-encapsulation facility in Orange County, NY, and the European Commission's implementation of 95.4% to 120.8% anti-dumping duties on Chinese choline chloride imports.
Balchem Corporation (NASDAQ: BCPC) has scheduled its second quarter 2025 financial results conference call for July 31, 2025, at 11:00 AM Eastern Time. The company's Chairman, President and CEO Ted Harris, along with CFO Martin Bengtsson, will host the call.
The Q2 2025 results will be released before market opening on the same day and will be available on www.balchem.com. Institutional investors and analysts can join by dialing 800-715-9871 (USA/Canada toll-free). A live webcast and replay will be accessible at the company's investor events portal.
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer focused on health and nutrition markets, has announced its participation in the upcoming CJS Annual New Ideas Summer Conference on July 10, 2025. The company will be represented by key executives including Ted Harris (Chairman, CEO, and President), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director Investor Relations).
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer focused on health and nutrition markets, has announced its participation in the upcoming Wells Fargo Industrials and Materials Conference scheduled for June 11, 2025. The company will be represented by key executives including Ted Harris (Chairman of the Board, CEO, and President), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director Investor Relations) who will present at the conference.
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer focusing on health and nutrition markets, has announced its participation in the upcoming dbAccess Global Consumer Conference scheduled for June 4, 2025. The company will be represented by Ted Harris, who serves as Chairman of the Board, Chief Executive Officer, and President, along with Martin Bengtsson, the Chief Financial Officer.
Balchem (NASDAQ: BCPC) reported strong Q1 2025 financial results with record net sales of $250.5 million, up 4.5% year-over-year. The company achieved net earnings of $37.1 million, a 27.8% increase, and record adjusted EBITDA of $66.3 million, up 8.9% from the prior year quarter.
All three segments - Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products - showed sales and earnings growth. The Human Nutrition segment led with record sales of $158.5 million, while gross margin improved to 35.2%, up 120 basis points. Operating expenses decreased to $37.2 million, and free cash flow was $31.0 million.
The company maintains a strong financial position with $49.9 million in cash and continues to invest in growth initiatives despite global trade uncertainties.
Balchem (NASDAQ: BCPC) has released its 2024 Sustainability Report, highlighting significant progress in environmental and social initiatives. The company has exceeded its 2030 greenhouse gas emissions reduction target, achieving a 32% reduction from the 2020 baseline, surpassing the original 25% goal.
Key achievements include:
- Approximately 70% of revenue supports UN Sustainable Development Goals
- 15% reduction in water withdrawal compared to 2020 baseline
- Improved safety metrics with TRIR at 0.57 and LTIR at 0.21
- Fourth anniversary of commitment to UN Global Compact
CEO Ted Harris emphasized Balchem's dual focus on providing innovative health and nutritional solutions while maintaining excellence in stewarding people, communities, and shareholders. The company remains aligned with UN SDGs focusing on zero hunger, good health and well-being, and responsible consumption and production.